Please login to the form below

Not currently logged in
Email:
Password:

CeNeS stock rockets on takeover hint

Cambridge-based biotechnology company CeNeS saw its share price soar this week after it revealed that it was in talks with a prospective purchaser.

Cambridge-based biotechnology company CeNeS saw its share price soar this week after it revealed that it was in talks with a prospective purchaser. No offer has yet been confirmed though the firm, whose share price on January 31 had been sitting at rock bottom (around 30p), saw its value on the AIM market rise on speculation by more than 60 per cent (at 16:00 February 5). It declined to comment on the source of its takeover approach.

Late last year, the company said it had anticipated securing a licensing deal for its lead product in 2008, however, analysts were surprised by the potential takeover news this week having observed CeNeS's value decline progressively in 2007, lagging behind the UK pharma and biotech market significantly. According to reports, the company had been struggling to get any products to market, hampered by issues at the evaluation stage.

The firm's main therapy focus is analgesia, with its lead compound (M6G) in phase III studies for post-operative pain. It's also developing CNS 5161 for neuropathic pain (phase II) and CNS 7056, a short-acting sedative in preclinical tests. The company also lists a potential COMT (catechol-omethyl transferase) inhibitor candidate for Parkinson's disease and/or schizophrenia.

With CeNeS's strong focus on pain, Collins Stewart analyst Navid Malik speculated that any purchaser of the firm would likely also be a key player in the analgesia market. An announcement on whether or not an offer has been made formally is anticipated soon.

2nd September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics